Peroxisome Proliferator-activated Receptors and Hepatic Stellate Cell Activation
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
The present study examined the roles of peroxisome proliferator-activated receptors (PPAR) in activation of hepatic stellate cells (HSC), a pivotal event in liver fibrogenesis. RNase protection assay detected mRNA for PPARgamma1 but not that for the adipocyte-specific gamma2 isoform in HSC isolated from sham-operated rats, whereas the transcripts for neither isoforms were detectable in HSC from cholestatic liver fibrosis induced by bile duct ligation (BDL). Semi-quantitative reverse transcriptase-polymerase chain reaction confirmed a 70% reduction in PPARgamma mRNA level in HSC from BDL. Nuclear extracts from BDL cells showed an expected diminution of binding to PPAR-responsive element, whereas NF-kappaB and AP-1 binding were increased. Treatment of cultured-activated HSC with ligands for PPARgamma (10 microm 15-deoxy-Delta(12,14)-PGJ(2) (15dPGJ(2)); 0.1 approximately 10 microm BRL49653) inhibited DNA and collagen synthesis without affecting the cell viability. Suppression of HSC collagen by 15dPGJ(2) was abrogated 70% by the concomitant treatment with a PPARgamma antagonist (GW9662). HSC DNA and collagen synthesis were inhibited by WY14643 at the concentrations known to activate both PPARalpha and gamma (>100 microm) but not at those that only activate PPARalpha (<10 microm) or by a synthetic PPARalpha-selective agonist (GW9578). 15dPGJ(2) reduced alpha1(I) procollagen, smooth muscle alpha-actin, and monocyte chemotactic protein-1 mRNA levels while inducing matrix metalloproteinase-3 and CD36. 15dPGJ(2) and BRL49653 inhibited alpha1(I) procollagen promoter activity. Tumor necrosis factor alpha (10 ng/ml) reduced PPARgamma mRNA, and this effect was prevented by the treatment with 15dPGJ(2). These results demonstrate that HSC activation is associated with the reductions in PPARgamma expression and PPAR-responsive element binding in vivo and is reversed by the treatment with PPARgamma ligands in vitro. These findings implicate diminished PPARgamma signaling in molecular mechanisms underlying activation of HSC in liver fibrogenesis and the potential therapeutic value of PPARgamma ligands for liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![FIG. 4 A , PPAR g (15dPGJ2, BRL49653) ligands inhibit HSC DNA and collagen synthesis. The 3-4-day primary cultures of HSC were exposed to 15dPGJ2 (1 and 10 m M), BRL49653 (1 and 10 m M), or WY14643 (10 ; 250 m M) for 18 h, and [ 3 H]thymidine incorporation into DNA was assessed. Note a significant, ; 40%, inhibition in HSC DNA synthesis by 15dPGJ2 and BRL49653 at 10 m M and WY14643 at 100 and 250 m M. *, p , 0.05; **, p , 0.01 compared with the respective control. DMSO , Me2SO. B , collagen production by cultured HSC, as determined by incorporation of [ 3 H]proline into collagenase-sensitive peptides was significantly inhibited by 18 h of treatment with 15dPGJ 2 (10 m M), BRL49653 (0.1 ; 10 m M), and WY14643 (100 m M). *, p , 0.05; **,](https://figures.cochat.ai/paper-figures/a66e36c4743842c5bde9349747bed49a/peroxisome-proliferator-activated-receptors-and-hepatic-stellate-cell-activation-figure-4.png)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“bezafibrate, a broad peroxisome proliferator-activated receptor (PPAR) agonist with anticholestatic, 14 anti-inflammatory, 15 and antifibrotic 16 properties”
From Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial (2021) · cites this paper as [16]
Experimental — accuracy not yet measuredIn the citing paper
“HSC activation is therefore associated with low levels of PPAR-γ expression, and the assumed relation between PPAR-γ and liver fibrosis was confirmed in an experimental restoration of PPAR-γ levels in HSCs, which resulted in a regression of aHSCs to quiescence state.[126,127]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [126]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
Schreiber, E., Matthias, P., Müller, M. M., & Schaffner, W. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.15.6419 · Cited by 4,179
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Self-citationThomas, A. C., & Campbell, J. H. (2000) · Cited by 2,800
A human retinoic acid receptor which belongs to the family of nuclear receptors
Petkovich, M., Brand, N. J., Krust, A., & Chambon, P. (1987) · Nature · doi:10.1038/330444a0 · Cited by 2,214
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816
Self-citationPPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797
The Cellular Basis of Hepatic Fibrosis -- Mechanisms and Treatment Strategies
Flier, J. S., Underhill, L. H., & Friedman, S. L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306243282508 · Cited by 1,432
The PPARα–leukotriene B4 pathway to inflammation control
Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., & Wahli, W. (1996) · Nature · doi:10.1038/384039a0 · Cited by 1,345
Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., & Santoro, M. G. (2000) · Nature · doi:10.1038/47520 · Cited by 1,310
Research works printed but not linked: 9
- Friedman, S. L., Wei, S., and Blaner, W. S. (1993) Am. J. Physiol. 264, G947-G952
- Tsukamoto, H., Cheng, S., and Blaner, W. S. (1996) Am. J. Physiol. 270, G581-G586
- Salbert, G., Fanjul, A., Piedrafita, F. J., Lu, X. P., Kim, S. J., Tran, P., and Pfahl, M. (1993) Mol. Endocrinol. 7, 1347-1356
- Okuno, M., Moriwaki, H., Imai, S., Muto, Y., Kawada, N., Suzuki, Y., and Kojima, S. (1997) Hepatology 26, 913-921
- Potter, J. J., Womack, L., Mezey, E., and Anania, F. A. (1998) Biochem. Cell Biol.244, 178 -182
- Lin, M., Rippe, R. A., Niemela, O., Brittenham, G., and Tsukamoto, H. (1997) Am. J. Physiol. 272, G1355-G1364
- Rippe, R. A., Almounajed, G., and Brenner, D. A. (1995) Hepatology 22, 241-251
- Zhang, B., Berger, J., Hu, E., Szalkowski, D., White-Carrington, S., Spiegelman, B. M., and Moller, D. E. (1996) Mol. Endocrinol. 10, 1457-1466
- Tsukamoto, H. (1999) Alcohol Clin. Exp. Res. 23, 911-916 · doi:10.1111/j.1530-0277.1999.tb04202.x · Paper page
Cited by
Items 101–200 of 477
Zisser, A., Ipsen, D. H., & Tveden-Nyborg, P. (2021) · Biomedicines · doi:10.3390/biomedicines9040365 · Cited by 104
Regulation of peroxisome proliferator-activated receptor-γ in liver fibrosis
Yang, L., Chan, C.-C., Kwon, O.-S., Liu, S., McGhee, J., Stimpson, S. A., Chen, L. Z., Harrington, W. W., Symonds, W. T., & Rockey, D. C. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00124.2006 · Cited by 109
Lin, J., Tang, Y., Kang, Q., Feng, Y., & Chen, A. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01910.x · Cited by 114
“Endogenous PPARg is highly expressed in quiescent HSC and is functionally active (Galli et al., 2000; Marra et al., 2000; Miyahara et al., 2000).”
BackgroundChen, A., & Zheng, S. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707542 · Cited by 111
“Stimulating PPARg activity by its agonists inhibits HSC proliferation and a1(I) collagen expression in vitro and in vivo (Miyahara et al., 2000; Galli et al., 2002).”
BackgroundInfluentialThe next generation of PPAR drugs: Do we have the tools to find them?
SHEARER, B. G., & Billin, A. N. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.05.005 · Cited by 124
Hayashizaki, Y., Kurosaki, E., Takasu, T., Mitori, H., Yamazaki, S., Koide, K., & Takakura, S. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.02.009 · Cited by 112
“Further, direct inhibition of pioglitazone of hepatic stellate cells activation (Miyahara et al., 2000; Marra et al., 2000; Galli et al., 2000, 2002) might also contribute to the attenuation of hepatic fibrosis.”
BackgroundPioglitazone Prevents Early-Phase Hepatic Fibrogenesis Caused by Carbon Tetrachloride
Kon, K., Ikejima, K., Hirose, M., Yoshikawa, M., Enomoto, N., Kitamura, T., Takei, Y., & Sato, N. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6385 · Cited by 109
Kang, Q., & Chen, A. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00261.x · Cited by 111
“Prior experiments have suggested that 10% of FBS in the medium contains enough agonists to activate PPARg in HSCs (Miyahara et al., 2000; Xu et al., 2003; Zheng and Chen, 2004).”
BackgroundMethodPanebianco, C., Oben, J. A., Vinciguerra, M., & Pazienza, V. (2016) · Clinical and Experimental Medicine · doi:10.1007/s10238-016-0438-x · Cited by 112
Boelsterli, U. A., & Bedoucha, M. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00817-6 · Cited by 111
Han, S., Sidell, N., Fisher, P. B., & Roman, J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0985 · Cited by 113
Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases
Halilbasic, E., Baghdasaryan, A., & Trauner, M. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.12.001 · Cited by 99
“In HSCs from BDL mice developing biliary cirrhosis, PPARg expression and DNA binding was dramatically reduced, demonstrating that HSC activation is associated with the reductions in PPARg expression.(180)”
BackgroundBourd-Boittin, K., Bonnier, D., Leyme, A., Mari, B., Tuffery, P., Samson, M., Ezan, F., Baffet, G., & Theret, N. (2010) · Hepatology · doi:10.1002/hep.24598 · Cited by 94
Grigorian, A. Y., Mardini, H. E., Corpechot, C., Poupon, R., & Levy, C. (2015) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2015.02.011 · Cited by 99
Novel PPARγ Modulator GED-0507-34 Levo Ameliorates Inflammation-driven Intestinal Fibrosis
Speca, S., Rousseaux, C., Dubuquoy, C., Rieder, F., Vetuschi, A., Sferra, R., Giusti, I., Bertin, B., Dubuquoy, L., Gaudio, E., et al. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000618 · Cited by 101
Thibaut, R., Gage, M. C., Pineda‐Torra, I., Chabrier, G., Venteclef, N., & Alzaid, F. (2022) · The FEBS Journal · doi:10.1111/febs.15877 · Cited by 95
Baghdasaryan, A., Claudel, T., Kosters, A., Gumhold, J., Silbert, D., Thüringer, A., Leski, K., Fickert, P., Karpen, S. J., & Trauner, M. (2010) · Gut · doi:10.1136/gut.2009.186528 · Cited by 96
Nonalcoholic fatty liver disease: new treatments
Hardy, T., Anstee, Q. M., & Day, C. P. (2015) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000175 · Cited by 89
Adiponectin is an endogenous anti-fibrotic mediator and therapeutic target
Marangoni, R. G., Masui, Y., Fang, F., Korman, B., Lord, G., Lee, J., Lakota, K., Wei, J., Scherer, P. E., Otvos, L., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04162-1 · Cited by 95
Zhou, Y., Zheng, S., Lin, J., Zhang, Q.-J., & Chen, A. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700532 · Cited by 96
In vitro reversion of activated primary human hepatic stellate cells
El Taghdouini, A., Najimi, M., Sancho-Bru, P., Sokal, E., & van Grunsven, L. A. (2015) · Fibrogenesis & Tissue Repair · doi:10.1186/s13069-015-0031-z · Cited by 91
“The loss of PPARγ activity, the master regulator of adipogenesis, has been found to play an important role during HSC activation [44–46], and overexpression in activated HSCs has been shown to induce a phenotypic switch to a more quiescent-like phenotype [11].”
BackgroundLeptin and liver fibrosis: A matter of fat
Marra, F. (2002) · Gastroenterology · doi:10.1053/gast.2002.33369 · Cited by 102
Hepatic PPARs: Their Role in Liver Physiology, Fibrosis and Treatment
Zardi, E., Navarini, L., Sambataro, G., Piccinni, P., Sambataro, F., Spina, C., & Dobrina, A. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990136 · Cited by 90
“A number of studies have elucidated that PPAR stimulation and expression inhibit HSCs activation and proliferation and, consequently, collagen secretion, both in vitro and in vivo [4].”
BackgroundInfluentialFarglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection
McHutchison, J. G., Goodman, Z. D., Patel, K., Makhlouf, H. R., Rodriguez‐Torres, M., Shiffman, M. L., Rockey, D. C., Husa, P., Chuang, W., Levine, R. A., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.12.003 · Cited by 91
Anti‐adipogenic regulation underlies hepatic stellate cell transdifferentiation
Tsukamoto, H., She, H., Hazra, S., Cheng, J., & Miyahara, T. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04573.x · Cited by 87
Self-citationCirculating markers of liver fibrosis progression
Jarčuška, P., Janíčko, M., Veselíny, E., Jarčuška, P., & Skladaný, Ľ. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.04.009 · Cited by 97
“Activation of hepatic stellatae cells results in down-regulation of PPARγ receptors, but administration of surplus ligands restores their expression and is accompanied by suppression of activated phenotype [27].”
BackgroundTang, Y., Zheng, S., & Chen, A. (2009) · Endocrinology · doi:10.1210/en.2008-1601 · Cited by 91
“The reduction in the level of PPAR coincides with HSC activation (38, 45, 46).”
BackgroundZhao, X., Ou, Z., Grotta, J. C., Waxham, M. N., & Aronowski, J. A. (2006) · Brain Research · doi:10.1016/j.brainres.2005.12.061 · Cited by 100
Chen, A., Tang, Y., Davis, V., Hsu, F.-F., Kennedy, S. M., Song, H., Turk, J., Brunt, E. M., Newberry, E. P., & Davidson, N. O. (2013) · Hepatology · doi:10.1002/hep.26318 · Cited by 87
“Basal expression of PPARc in the liver is relatively low,37 yet PPARc is highly expressed in steatotic liver in obese mice38 and in human subjects.39 Although some studies suggest an antisteatotic role for Pparc,40,41 others have indicated that hepatic Pparc is prosteatotic.27,42-44 Pparc is abundantly expressed in qu…”
BackgroundInfluentialMAREK, C. J., TUCKER, S. J., KONSTANTINOU, D. K., ELRICK, L. J., HAEFNER, D., SIGALAS, C., MURRAY, G. I., GOODWIN, B., & WRIGHT, M. C. (2005) · Biochemical Journal · doi:10.1042/bj20041598 · Cited by 89
Zhang, F., Kong, D., Lu, Y., & Zheng, S. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1046-x · Cited by 92
“to PPRE was dramatically impaired in activated HSCs, but treatment with PPARc agonists was able to prevent HSC activation [35].”
BackgroundRumi, M. A. K., Sato, H., Ishihara, S., Kawashima, K., Hamamoto, S., Kazumori, H., Okuyama, T., Fukuda, R., Nagasue, N., & Kinoshita, Y. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1821 · Cited by 93
“…inhibitory potential on hepatocellular carcinom cells through induction of G1 cell cycle arrest and recent stud have also shown that activation of PPARγ can inhibit the profibrogenic and proinflammatory actions of hepatic stellate cells (G et al, 2000; Marra et al, 2000; Miyahara et al, 2000).”
BackgroundLin, J., & Chen, A. (2008) · Laboratory Investigation · doi:10.1038/labinvest.2008.20 · Cited by 95
“In many cell types, gene expression of PDGFbR and EGFR is associated with increase in oxidative stress, which might represent pathophysiological determinants.51–53 Additional experiments are necessary to elucidate the underlying mechanisms by which oxidative stress regulates pdgf-br and egfr expression in HSCs. Based…”
BackgroundInfluentialSchneiderhan, W., Schmid-Kotsas, A., Zhao, J., Grünert, A., Nüssler, A., Weidenbach, H., Menke, A., Schmid, R. M., Adler, G., & Bachem, M. G. (2001) · Hepatology · doi:10.1053/jhep.2001.27828 · Cited by 86
Hepatic Stellate Cell-derived Delta-like Homolog 1 (DLK1) Protein in Liver Regeneration
Zhu, N.-L., Asahina, K., Wang, J., Ueno, A., Lazaro, R., Miyaoka, Y., Miyajima, A., & Tsukamoto, H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.312751 · Cited by 85
“Indeed, our research demonstrates that adipogenic transcription regulation is required for HSC differentiation (3, 4), and a loss of this regulation underlies HSC transdifferentiation into myofibroblastic cells (4, 5) where canonicalWnt signaling is shown to play a major role (6) much like in inhibition of adipogenesi…”
BackgroundSelf-citationZheng, S., & Chen, A. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00450.2005 · Cited by 89
“Prior studies have implicated a potential therapeutic value of PPAR- activation in the treatment of liver fibrosis (23, 34, 37).”
BackgroundVesterhus, M., & Karlsen, T. H. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01681-z · Cited by 80
Karsdal, M. A., Henriksen, K., Nielsen, M. J., Byrjalsen, I., Leeming, D. J., Gardner, S., Goodman, Z., Patel, K., Krag, A., Christiansen, C., et al. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00283.2016 · Cited by 82
Translating an Understanding of the Pathogenesis of Hepatic Fibrosis to Novel Therapies
Rockey, D. C. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.01.005 · Cited by 79
The Roles of Peroxisome Proliferator-Activated Receptors in the Metabolic Syndrome
Mansour, M. M. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-800101-1.00007-7 · Cited by 83
Yu, J. Q., Zhang, S., Chu, E. S., Go, M. Y. Y., Lau, R. H. Y., Zhao, J., Wu, C., Tong, L., Zhao, J., Poon, T. C. W., et al. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.02.006 · Cited by 84
Méndez, M., & LaPointe, M. C. (2003) · Hypertension · doi:10.1161/01.hyp.0000085332.69777.d1 · Cited by 90
Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities
Manka, P., Zeller, A., & Syn, W.-K. (2019) · Drugs · doi:10.1007/s40265-019-01126-9 · Cited by 76
Heme oxygenase-1 is an antifibrogenic protein in human hepatic myofibroblasts
Li, L., Grenard, P., Nhieu, J. T. V., Julien, B., Mallat, A., Habib, A., & Lotersztajn, S. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00906-5 · Cited by 82
Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells
Li, J., Zhang, Y., Kuruba, R., Gao, X., Gandhi, C. R., Xie, W., & Li, S. (2011) · Molecular Pharmacology · doi:10.1124/mol.110.068247 · Cited by 78
“Several studies have shown that nuclear receptors such as peroxisome proliferator-activated receptor and pregnane X receptor also play an important role in the modulation of HSC activation and their biologic functions (Miyahara et al., 2000; Galli et al., 2002; Marek et al., 2005).”
BackgroundWei, J., Bhattacharyya, S., & Varga, J. (2010) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32833de1a7 · Cited by 74
Zheng, S., & Chen, A. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00200.2006 · Cited by 77
Wei, J., Zhu, H., Komura, K., Lord, G., Tomčík, M., Wang, W., Doniparthi, S., Tamaki, Z., Hinchcliff, M., Distler, J. H. W., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202716 · Cited by 84
Choi, J. H., Jin, S. W., Choi, C. Y., Kim, H. G., Lee, G. H., Kim, Y.-A., Chung, Y., & Jeong, H. G. (2016) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6b04805 · Cited by 78
Hepatic insulin receptor: new views on the mechanisms of liver disease
Lee, W., Najjar, S. M., Kahn, C. R., & Hinds, T. D. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155607 · Cited by 79
Effect of overexpression of pparγ on the healing process of corneal alkali burn in mice
Saika, S., Yamanaka, O., Okada, Y., Miyamoto, T. K., Kitano, A., Flanders, K. C., Ohnishi, Y., Nakajima, Y., Kao, W. W. ‐., & Ikeda, K. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00332.2006 · Cited by 81
“Although all of the signaling networks linked to PPAR are not fully described, stimulation of this receptor by ligand application results in reduction of the fibrogenic response and myofibroblast generation in cultures of hepatic stellate cells (22, 33, 36, 62) and lung fibroblasts (4, 65), suggesting potential effica…”
BackgroundTargeting hepatic stellate cells for cell-specific treatment of liver fibrosis
Beljaars, L., Meijer, D. K. F., & Poelstra, K. (2002) · Frontiers in bioscience · doi:10.2741/a917 · Cited by 77
McVicker, B. L., & Bennett, R. G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00318 · Cited by 85
“Early studies of liver myofibroblasts (hepatic stellate cells, or HSCs) revealed that PPARγ expression was present in quiescent HSC, but was reduced with activation to the myofibroblastic phenotype and fibrosis progression (Galli et al., 2000; Marra et al., 2000; Miyahara et al., 2000).”
BackgroundAdipogenic Phenotype of Hepatic Stellate Cells
Tsukamoto, H. (2005) · Alcoholism: Clinical and Experimental Research · doi:10.1097/01.alc.0000189279.92602.f0 · Cited by 73
Self-citationInhibition of markers of hepatic stellate cell activation by the hormone relaxin
Bennett, R. G., Kharbanda, K. K., & Tuma, D. J. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00403-9 · Cited by 75
TIPs Are Tension-Responsive Proteins Involved in Myogenic versus Adipogenic Differentiation
Jakkaraju, S., Zhe, X., Pan, D., Choudhury, R., & Schuger, L. A. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.04.015 · Cited by 79
Curcumin: A Naturally Occurring Modulator of Adipokines in Diabetes
Hajavi, J., Momtazi‐Borojeni, A. A., Johnston, T. P., Banach, M., Majeed, M. A., & Sahebkar, A. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26121 · Cited by 74
Epigenetic Mechanisms in Hepatic Stellate Cell Activation During Liver Fibrosis and Carcinogenesis
Barcena-Varela, M., Colyn, L., & Fernandez-Barrena, M. G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102507 · Cited by 72
“PPARγ reinforces their adipogenic phenotype, but when HSCs become activated, PPARγ expression and activity are downregulated [70,71].”
BackgroundFibroblast activation protein and chronic liver disease
Wang, X. M., Yao, T.-W., Nadvi, N. A., Osborne, B., McCaughan, G. W., & Gorrell, M. D. (2007) · Frontiers in bioscience · doi:10.2741/2918 · Cited by 75
“PPAR-gamma ligands suppress DNA synthesis, CN production, alpha–smooth muscle actin expression and PDGF-induced HSC migration (75).”
BackgroundYu, Q., Cheng, P., Wu, J., & Guo, C. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16267 · Cited by 74
Iron-induced oxidant stress in alcoholic liver fibrogenesis
Pietrangelo, A. (2003) · Alcohol · doi:10.1016/s0741-8329(03)00126-5 · Cited by 74
“Peroxisome proliferator-activated receptor-gamma expression is inversely related to hepatic stellate cell activation and proliferation (Galli et al., 2000; Marra et al., 2000; Miyahara et al., 2000), and ligands for such receptors (thiazolidinediones) block fibrosis related to various causes (Galli et al.”
BackgroundLimited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats
Leclercq, I. A. (2006) · Gut · doi:10.1136/gut.2005.079194 · Cited by 67
Wang, C., Liu, Q., Huang, Q., Liu, J. T., He, Y. H., Lu, J., & Bai, X. (2013) · Phytomedicine · doi:10.1016/j.phymed.2013.02.001 · Cited by 69
“In addition, PPAR ligands can inhibit collagen or fibronectin synthesis induced by TGF- 1 in HSCs (Miyahara et al. 2000; Galli et al. 2002).”
BackgroundMorgenweck, J., Abdel‐Aleem, O. S., McNamara, K. C., Donahue, R. R., Badr, M. Z., & Taylor, B. K. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.10.008 · Cited by 74
“To test the hypothesis that PPARg receptors mediate the antiinflammatory actions of rosiglitazone and 15d-PGJ2, we used two compounds thought to selectively antagonize the PPARg isoforms: GW9662 (Miyahara et al., 2000) and BADGE.”
PPAR Gamma and Hepatic Stellate Cells
Hazra, S., Miyahara, T., Rippe, R. A., & Tsukamoto, H. (2004) · Comparative Hepatology · doi:10.1186/1476-5926-2-s1-s7 · Cited by 66
“al demonstrated that 15dPGJ2 and BRL49653 (rosiglitazone) suppressed DNA synthesis by 40–50% in cultured activated HSC [4].”
BackgroundResultSelf-citationPark, J., Ki, M.-R., Lee, H.-R., Hong, I., Ji, A., Ishigami, A., Park, S., Kim, J., Chung, H., Yoo, S., et al. (2009) · Hepatology · doi:10.1002/hep.23499 · Cited by 71
Kang, Q., & Chen, A. (2009) · Laboratory Investigation · doi:10.1038/labinvest.2009.93 · Cited by 64
“Transfected cells were cultured for 24 h in media with 10% FBS, which contains enough agonists to activate PPARg in HSCs.(19,23,24) Luciferase activity assays in Figure 10b revealed that forced expression of PPARg dose dependent reduced luciferase activities in cells transfected with TOPflash, but not in cells transfe…”
MethodZhang, W., Conway, S. J., Liu, Y., Snider, P. L., Chen, H., Gao, H., Liu, Y., Isidan, K., Lopez, K., Campaña, G., et al. (2021) · Cells · doi:10.3390/cells10082129 · Cited by 69
“Upon liver injury, HSCs reduce the expression of genes such as peroxisome proliferator-activated receptor gamma (PPARγ) [3], lose lipid droplets, and activate into myofibroblasts by starting to express genes that encode contractile proteins and extracellular fibrogenic genes such alpha-smooth muscle actin (α-SMA) and…”
BackgroundZhang, F., Lu, Y., & Zheng, S. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.11.008 · Cited by 73
PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs
Peyrou, M., Ramadori, P., Bourgoin, L., & Foti, M. (2012) · PPAR Research · doi:10.1155/2012/757803 · Cited by 70
“Obesity, the metabolic syndrome (MetS), diabetes, hepatitis viruses (HBV/HCV), and abusive alcohol consumption are currently the principal etiological factors favoring the occurrence of hepatocellular adenoma and carcinoma worldwide [1–8].”
BackgroundMethionine adenosyltransferases in liver health and diseases
Ramani, K., & Lu, S. C.-L. (2017) · Liver Research · doi:10.1016/j.livres.2017.07.002 · Cited by 70
Bile acid homeostasis paradigm and its connotation with cholestatic liver diseases
Yang, T., Khan, G. J., Wu, Z., Wang, X., Zhang, L., & Jiang, Z. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.007 · Cited by 65
Hellemans, K., Rombouts, K., Quartier, E., Dittié, A. S., Knorr, A., Michalik, L., Rogiers, V., Schuit, F., Wahli, W., & Geerts, A. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m200376-jlr200 · Cited by 64
Human immunodeficiency virus infection and the liver
Crane, M., Iser, D., & Lewin, S. R. (2012) · World Journal of Hepatology · doi:10.4254/wjh.v4.i3.91 · Cited by 64
Tang, Y., & Chen, A. (2010) · Endocrinology · doi:10.1210/en.2010-0191 · Cited by 65
“Prior experiments have suggested that 10% of FBS in the medium contains enough agonists to activate PPAR in HSCs (8, 30, 31).”
BackgroundSung, C. K., She, H., Xiong, S., & Tsukamoto, H. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00411.2003 · Cited by 63
Self-citationYavrom, S., Chen, L., Xiong, S., Wang, J., Rippe, R. A., & Tsukamoto, H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m510094200 · Cited by 62
Self-citationZhang, D., Zhuang, R., Guo, Z., Gao, M., Huang, L., You, L., Zhang, P., Li, J., Su, X., Wu, H., et al. (2018) · Theranostics · doi:10.7150/thno.22806 · Cited by 65
Difficulty with diagnosis of malignant pancreatic neoplasms coexisting with chronic pancreatitis
Leung, T.-K. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i32.4931 · Cited by 59
“downregulate several biologic actions of activated HSC, which are important for liver wound healing and fibrogenesis, including cell proliferation, migration, extracellular matrix synthesis, and expression of chemokines[ 13-15 ].”
BackgroundKang, Q., & Chen, A. (2009) · Endocrinology · doi:10.1210/en.2009-0517 · Cited by 60
Han, S., & Sidell, N. (2002) · Immunology · doi:10.1046/j.1365-2567.2002.01404.x · Cited by 59
Jaster, R., Lichte, P., Fitzner, B., Brock, P., Glass, A. S., Karopka, T., Gierl, L., Koczan, D., Thiesen, H., Sparmann, G. H., et al. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00497.x · Cited by 64
Epigenetic cell fate regulation of hepatic stellate cells
Tsukamoto, H., Zhu, N., Asahina, K., Mann, D. A., & Mann, J. (2011) · Hepatology Research · doi:10.1111/j.1872-034x.2011.00804.x · Cited by 57
Self-citationWei, J., Bhattacharyya, S., Jain, M., & Varga, J. (2012) · The Open Rheumatology Journal · doi:10.2174/1874312901206010103 · Cited by 67
Lin, J., & Chen, A. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.12.028 · Cited by 59
Hernández‐Aquino, E., Quezada‐Ramírez, M. A., Silva-Olivares, A., Casas‐Grajales, S., Ramos‐Tovar, E., Flores‐Beltrán, R. E., Segovia, J., Shibayama, M., & Muriel, P. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172730 · Cited by 60
Castilho–Fernandes, A., de Almeida, D. C., Fontes, A. M., Melo, F. U. F., Picanço‐Castro, V., de Freitas, M. C. C., Orellana, M. D., Palma, P. V. B., Hackett, P. B., Friedman, S. L., et al. (2011) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2011.09.002 · Cited by 60
Zhu, N., Wang, J., & Tsukamoto, H. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.156703 · Cited by 55
Self-citationPeroxisome proliferator-activated receptor gamma inhibits hepatic fibrosis in rats
Wang, Z., Xu, J.-P., Zheng, Y.-C., Chen, W., Sun, Y.-W., Wu, Z.-Y., & Luo, M. (2011) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(11)60009-x · Cited by 59
Schistosoma mansoni: Egg-induced downregulation of hepatic stellate cell activation and fibrogenesis
Anthony, B. J., Mathieson, W., Castro‐Borges, W., & Allen, J. (2010) · Experimental Parasitology · doi:10.1016/j.exppara.2009.12.009 · Cited by 55
Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro
Routh, R. E., Johnson, J. H., & McCarthy, K. J. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00277.x · Cited by 58
“The lack of effect of PPAR-a agonists on extracellular matrix (ECM) synthesis by cells has been observed in other cell system”
BackgroundOkazaki, I., Noro, T., Tsutsui, N., Yamanouchi, E., Kuroda, H., Nakano, M., Yokomori, H., & Inagaki, Y. (2014) · Cancers · doi:10.3390/cancers6031220 · Cited by 61
Molecular Mechanisms of Hepatic Fibrosis in Non-Alcoholic Steatohepatitis
Rombouts, K., & Marra, F. (2010) · Digestive Diseases · doi:10.1159/000282094 · Cited by 54
“], and TZDs are employed for the treatment of insulin resistance in patients with type 2 diabetes. PPAR-? is expressed in quiescent HSCs and decreases along the activation process that accompanies the acquisition of fibrogenic properties. Moreover, exposure of HSCs to PPAR-? ligands reverts most features of the activa…”
Akahori, T., Sho, M., Hamada, K., Suzaki, Y., Kuzumoto, Y., Nomi, T., Nakamura, S., Enomoto, K., Kanehiro, H., & Nakajima, Y. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.07.030 · Cited by 58
Roth, J. D., Veidal, S. S., Fensholdt, L. K. D., Rigbolt, K. T. G., Papazyan, R., Nielsen, J. C., Feigh, M., Vrang, N., Young, M., Jelsing, J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-45178-z · Cited by 53
Renga, B., Mencarelli, A., Migliorati, M., Cipriani, S., D’Amore, C., Distrutti, E., & Fiorucci, S. (2011) · Inflammation Research · doi:10.1007/s00011-010-0306-1 · Cited by 53
Leptin inhibits PPARγ gene expression in hepatic stellate cells in the mouse model of liver damage
Zhou, Y., Jia, X., Qin, J., Lu, C., Zhu, H., Li, X., Han, X., & Sun, X. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.03.005 · Cited by 55
Aoyama, T., Ikejima, K., Kon, K., Okumura, K., Arai, K., & Watanabe, S. (2009) · Hepatology · doi:10.1002/hep.22828 · Cited by 52
Demetris, A. J. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i22.3512 · Cited by 50
Effectiveness of the PPARγ agonist, GW570, in liver fibrosis
Yang, L., Stimpson, S. A., Chen, L., Harrington, W. W., & Rockey, D. C. (2010) · Inflammation Research · doi:10.1007/s00011-010-0226-0 · Cited by 57
“PPARc is particularly prominent in that it is markedly downregulated during activation [10, 11].”
Metadata
- Authors
- Miyahara, T., Schrum, L., Rippe, R., Xiong, S., Yee, H. F., Motomura, K., Anania, F. A., Willson, T. M., & Tsukamoto, H.
- Affiliations
- University of Southern California (US)
- University of North Carolina at Chapel Hill (US)
- University of California, Los Angeles (US)
- University of Maryland, College Park (US)
- Corresponding author
- Tsukamoto, Hidekazu
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2000-11
- Volume
- 275
- Issue
- 46
- Pages
- 35715-35722
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2025657436
- Cited by
- 473
- References
- 56
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 8 · 2023: 9 · 2022: 12 · 2021: 17 · 2020: 18 · 2019: 14 · 2018: 14 · 2017: 19 · 2016: 16 · 2015: 22 · 2014: 21 · 2013: 17 · 2012: 25
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 7274 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- U.S. Department of Veterans Affairs
- University of Southern California (DK48522)
- National Institutes of Health (5k08dk002450-05, AA10459)
- National Institute on Alcohol Abuse and Alcoholism (AA10459, R37AA006603, R37-AA-06603, P50AA011999)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-02450)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- peroxisome proliferator-activated receptors, PPARγ, hepatic stellate cell activation, liver fibrosis, cholestatic liver fibrosis, bile duct ligation, PPAR ligands, collagen synthesis, PPAR-responsive element, TNF-α, matrix metalloproteinase-3
- MeSH terms
- Rosiglitazone, Animals, Cell Survival, Cells, Cultured, Collagen, DNA, Gene Expression Regulation, Liver, Liver Cirrhosis, Biliary, Liver Cirrhosis, Experimental, Male, Promoter Regions, Genetic, Protein Binding, Pyrimidines, RNA, Messenger, Thiazoles, Transcription Factors, Tumor Necrosis Factor-alpha, Prostaglandin D2, Rats, Wistar, Receptors, Cytoplasmic and Nuclear, Protein Isoforms, Thiazolidinediones, Cell Size, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.